|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RNF144A |
Gene summary for RNF144A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RNF144A | Gene ID | 9781 |
| Gene name | ring finger protein 144A | |
| Gene Alias | RNF144 | |
| Cytomap | 2p25.1 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | P50876 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9781 | RNF144A | male-WTA | Human | Thyroid | PTC | 1.03e-09 | 7.07e-02 | 0.1037 |
| 9781 | RNF144A | PTC01 | Human | Thyroid | PTC | 4.59e-02 | 3.03e-02 | 0.1899 |
| 9781 | RNF144A | PTC04 | Human | Thyroid | PTC | 1.13e-06 | 6.96e-02 | 0.1927 |
| 9781 | RNF144A | PTC05 | Human | Thyroid | PTC | 3.69e-06 | 1.48e-01 | 0.2065 |
| 9781 | RNF144A | PTC06 | Human | Thyroid | PTC | 1.11e-02 | 6.76e-02 | 0.2057 |
| 9781 | RNF144A | PTC07 | Human | Thyroid | PTC | 3.61e-05 | 7.56e-02 | 0.2044 |
| 9781 | RNF144A | ATC11 | Human | Thyroid | ATC | 1.92e-10 | 5.82e-01 | 0.3386 |
| 9781 | RNF144A | ATC12 | Human | Thyroid | ATC | 2.32e-29 | 7.01e-01 | 0.34 |
| 9781 | RNF144A | ATC13 | Human | Thyroid | ATC | 5.19e-53 | 1.05e+00 | 0.34 |
| 9781 | RNF144A | ATC2 | Human | Thyroid | ATC | 2.81e-07 | 7.28e-01 | 0.34 |
| 9781 | RNF144A | ATC3 | Human | Thyroid | ATC | 4.53e-09 | 4.76e-01 | 0.338 |
| 9781 | RNF144A | ATC4 | Human | Thyroid | ATC | 8.35e-34 | 8.05e-01 | 0.34 |
| 9781 | RNF144A | ATC5 | Human | Thyroid | ATC | 1.37e-66 | 1.11e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498113 | Thyroid | PTC | proteasomal protein catabolic process | 297/5968 | 490/18723 | 4.58e-40 | 9.63e-37 | 297 |
| GO:0043161113 | Thyroid | PTC | proteasome-mediated ubiquitin-dependent protein catabolic process | 254/5968 | 412/18723 | 3.91e-36 | 4.54e-33 | 254 |
| GO:0009896113 | Thyroid | PTC | positive regulation of catabolic process | 278/5968 | 492/18723 | 3.35e-30 | 2.64e-27 | 278 |
| GO:0031331113 | Thyroid | PTC | positive regulation of cellular catabolic process | 249/5968 | 427/18723 | 5.28e-30 | 3.58e-27 | 249 |
| GO:0042176113 | Thyroid | PTC | regulation of protein catabolic process | 231/5968 | 391/18723 | 4.76e-29 | 2.14e-26 | 231 |
| GO:1903362113 | Thyroid | PTC | regulation of cellular protein catabolic process | 162/5968 | 255/18723 | 1.62e-25 | 5.12e-23 | 162 |
| GO:1903050113 | Thyroid | PTC | regulation of proteolysis involved in cellular protein catabolic process | 140/5968 | 221/18723 | 4.63e-22 | 1.01e-19 | 140 |
| GO:0045732113 | Thyroid | PTC | positive regulation of protein catabolic process | 142/5968 | 231/18723 | 1.43e-20 | 2.38e-18 | 142 |
| GO:2000058113 | Thyroid | PTC | regulation of ubiquitin-dependent protein catabolic process | 110/5968 | 164/18723 | 1.83e-20 | 2.97e-18 | 110 |
| GO:0061136113 | Thyroid | PTC | regulation of proteasomal protein catabolic process | 121/5968 | 187/18723 | 2.25e-20 | 3.37e-18 | 121 |
| GO:0032434113 | Thyroid | PTC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 94/5968 | 134/18723 | 9.17e-20 | 1.23e-17 | 94 |
| GO:1903364113 | Thyroid | PTC | positive regulation of cellular protein catabolic process | 104/5968 | 155/18723 | 1.93e-19 | 2.39e-17 | 104 |
| GO:0045862113 | Thyroid | PTC | positive regulation of proteolysis | 198/5968 | 372/18723 | 6.68e-18 | 6.91e-16 | 198 |
| GO:1901800112 | Thyroid | PTC | positive regulation of proteasomal protein catabolic process | 80/5968 | 114/18723 | 4.80e-17 | 4.27e-15 | 80 |
| GO:1903052112 | Thyroid | PTC | positive regulation of proteolysis involved in cellular protein catabolic process | 88/5968 | 133/18723 | 4.30e-16 | 3.39e-14 | 88 |
| GO:0032436113 | Thyroid | PTC | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 66/5968 | 90/18723 | 7.51e-16 | 5.64e-14 | 66 |
| GO:2000060113 | Thyroid | PTC | positive regulation of ubiquitin-dependent protein catabolic process | 73/5968 | 107/18723 | 1.19e-14 | 7.75e-13 | 73 |
| GO:000020920 | Thyroid | PTC | protein polyubiquitination | 128/5968 | 236/18723 | 7.81e-13 | 3.65e-11 | 128 |
| GO:001049832 | Thyroid | ATC | proteasomal protein catabolic process | 309/6293 | 490/18723 | 1.78e-41 | 1.13e-37 | 309 |
| GO:0043161210 | Thyroid | ATC | proteasome-mediated ubiquitin-dependent protein catabolic process | 265/6293 | 412/18723 | 7.09e-38 | 1.49e-34 | 265 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RNF144A | SNV | Missense_Mutation | rs545761424 | c.539N>T | p.Ala180Val | p.A180V | P50876 | protein_coding | tolerated(0.22) | probably_damaging(0.989) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RNF144A | SNV | Missense_Mutation | c.751N>A | p.Val251Met | p.V251M | P50876 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-AR-A1AQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| RNF144A | SNV | Missense_Mutation | rs758418992 | c.862N>A | p.Asp288Asn | p.D288N | P50876 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.959) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| RNF144A | SNV | Missense_Mutation | c.428N>T | p.Cys143Phe | p.C143F | P50876 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-NH-A8F8-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD | |
| RNF144A | SNV | Missense_Mutation | novel | c.292N>A | p.Phe98Ile | p.F98I | P50876 | protein_coding | deleterious(0.01) | benign(0.089) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RNF144A | SNV | Missense_Mutation | novel | c.64N>T | p.Leu22Phe | p.L22F | P50876 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| RNF144A | SNV | Missense_Mutation | novel | c.610N>G | p.Lys204Glu | p.K204E | P50876 | protein_coding | deleterious(0) | benign(0.057) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RNF144A | SNV | Missense_Mutation | c.231G>T | p.Gln77His | p.Q77H | P50876 | protein_coding | tolerated(0.07) | probably_damaging(0.948) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RNF144A | SNV | Missense_Mutation | novel | c.596C>T | p.Ala199Val | p.A199V | P50876 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RNF144A | SNV | Missense_Mutation | c.421N>A | p.Glu141Lys | p.E141K | P50876 | protein_coding | tolerated(0.84) | probably_damaging(0.982) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |